Workflow
National Research (NRC)
icon
Search documents
National Research (NRC) - 2024 Q1 - Quarterly Results
2024-05-07 21:11
Exhibit 99.1 1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com Contact:Linda A. Stacy Principal Financial Officer 402-475-2525 NATIONAL RESEARCH CORPORATION ANNOUNCES FIRST QUARTER RESULTS LINCOLN, Nebraska (May 7, 2024) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: "NRC continues to be strongly positioned for growth in our expanding markets. O ...
National Research (NRC) - 2023 Q4 - Annual Report
2024-02-27 19:44
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer inco ...
National Research (NRC) - 2023 Q3 - Quarterly Report
2023-11-09 14:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State o ...
National Research (NRC) - 2023 Q3 - Earnings Call Transcript
2023-11-08 20:11
Financial Data and Key Metrics Changes - Revenue for Q3 2023 increased slightly compared to Q3 2022, ending the quarter with $144.3 million in Total Revenue Contract Value (TRCV) [22] - Operating income decreased by 10% for Q3 2023 compared to Q3 2022, primarily due to growth in certain costs exceeding revenue growth [22] - The effective tax rate in Q3 2023 was 22%, down from 23% in 2022, mainly due to lower state income taxes [4] Business Line Data and Key Metrics Changes - The Human Understanding Program saw an average contract value growth of 13% from existing clients, aligning with previous successful rollouts [15] - The sales force has increased by 19% since the beginning of the year to capitalize on growing demand, contributing to two consecutive quarters of double-digit sales growth compared to the prior year [15] Market Data and Key Metrics Changes - The company is expanding its product offerings to capture a larger total addressable market while gaining market share in the core patient experience market [3] Company Strategy and Development Direction - The company is focused on accelerating revenue growth and expanding margins, with a plan that has shown sequential improvement over the past two quarters [20] - Increased investments in marketing and cybersecurity services are aimed at expanding brand recognition and supporting sales development [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in seeing the results of their efforts reflected in revenue per associate and operating margin in future periods [21] - The company remains well-positioned to execute a range of capital allocation alternatives, including funding for innovation, shareholder dividends, and share repurchases [17] Other Important Information - The company incurred $661,000 in nonrecurring state tax incentive adjustments during the quarter [4] - As of September 30, 2023, the company had approximately $20 million in net debt and $25 million available on the line of credit after funding various expenditures [17] Q&A Session Summary - No specific questions or answers were documented in the provided content, as the call transitioned directly to closing remarks after the prepared comments [5][6][12]
National Research (NRC) - 2023 Q2 - Quarterly Report
2023-08-04 13:10
Table of Contents FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Ident ...
National Research (NRC) - 2023 Q1 - Quarterly Report
2023-05-05 13:47
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) Delaware 47- ...
National Research (NRC) - 2022 Q4 - Annual Report
2023-03-03 15:49
Table of Contents Delaware 47-0634000 1245 Q Street, Lincoln, Nebraska 68508 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as sp ...
National Research (NRC) - 2022 Q4 - Earnings Call Transcript
2023-02-15 17:39
National Research Corporation (NASDAQ:NRC) Q4 2022 Earnings Conference Call February 15, 2023 11:00 AM ET Company Participants Kevin Karas - CFO Linda Stacy - VP, Finance Conference Call Participants George D'Angelo - Alpine Peaks Capital Operator Hello, and welcome to the National Research Corporation Fourth Quarter 2022 Earnings Call. My name is Elliot and I'll be coordinating your call today. [Operator Instructions]. I would now like to hand over to Kevin Karas. The floor is yours. Please go ahead. Kevin ...
National Research (NRC) - 2022 Q3 - Earnings Call Transcript
2022-11-06 01:46
National Research Corporation (NASDAQ:NRC) Q3 2022 Earnings Conference Call November 3, 2022 10:00 AM ET Company Participants Linda Stacy - VP, Finance Kevin Karas - Chief Financial Officer Conference Call Participants George D'Angelo - Alpine Peaks Capital Operator Hello, and welcome to the National Research Corporation???s Third Quarter 2022 Earnings Call. My name is Bailey and I'll be your moderator for today's today. [Operator Instructions] I would now like to pass the call over to Kevin Karas, Chief F ...
National Research (NRC) - 2022 Q3 - Quarterly Report
2022-11-04 13:36
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State o ...